The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

Andrea Visentin; Thomas Chatzikonstantinou; Lydia Scarfò; Anargyros Kapetanakis; Christos Demosthenous; Georgios Karakatsoulis; Eva Minga; Dimitra Chamou; David Allsup; Alejandro Alonso Cabrero; Martin Andres; Darko Antic; Mónica Baile; Panagiotis Baliakas; Sotiria Besikli-Dimou; Dominique Bron; Sofia Chatzileontiadou; Raul Cordoba; Juan Gonzalo Correa; Carolina Cuéllar-García; Lorenzo De Paoli; Maria Rosaria De Paolis; Julio Delgado; Maria Dimou; David Donaldson; Mark Catherwood; Michael Doubek; Maria Efstathopoulou; Barbara Eichhorst; Salma Elashwah; Alicia Enrico; Blanca Espinet; Lucia Farina; Angela Ferrari; Myriam Foglietta; Henrik Frederiksen; Moritz Fürstenau; José A. García-Marco; Rocío García-Serra; Rosa Collado; Massimo Gentile; Eva Gimeno; Andreas Glenthøj; Maria Gomes da Silva; Yervand K. Hakobyan; Yair Herishanu; José Ángel Hernández-Rivas; Tobias Herold; Idanna Innocenti; Gilad Itchaki; Ozren Jaksic; Ann Janssens; Оlga B. Kalashnikova; Elżbieta Kalicińska; Arnon P. Kater; Sabina Kersting; Jorge Labrador; Deepesh Lad; Luca Laurenti; Mark David Levin; Enrico Lista; Alberto Lopez-Garcia; Lara Malerba; Roberto Marasca; Monia Marchetti; Juan Marquet; Mattias Mattsson; Francesca R. Mauro; Marta Morawska; Marina Motta; Talha Munir; Roberta Murru; Carsten U. Niemann; Raquel Nunes Rodrigues; Jacopo Olivieri; Lorella Orsucci; Maria Papaioannou; Miguel Arturo Pavlovsky; Inga Piskunova; Viola Maria Popov; Francesca Maria Quaglia; Giulia Quaresmini; Kristian Qvist; Gian Matteo Rigolin; Rosa Ruchlemer; Martin Šimkovič; Martin Špaček; Paolo Sportoletti; Oana Stanca; Tamar Tadmor; Antonella Capasso; Giovanni Del Poeta; Odit Gutwein; Linda Katharina Karlsson; Ivana Milosevic; Fatima Mirás; Gianluigi Reda; Gevorg Saghumyan; Amit Shrestha; Doreen Te Raa; Sanne H. Tonino; Ellen Van Der Spek; Michel van Gelder; Roel van Kampen; Ewa Wasik-Szczepanek; Tomasz Wróbel; Lucrecia Yáñez San Segundo; Mohamed Yassin; Barbara Pocali; Elisabeth Vandenberghe; Sunil Iyengar; Marzia Varettoni; Candida Vitale; Marta Coscia; Alessandro Rambaldi; Emili Montserrat; Antonio Cuneo; Niki Stavroyianni; Livio Trentin; Kostas Stamatopoulos; Paolo Ghia

doi:10.1002/ajh.27093

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, Anargyros Kapetanakis, Christos Demosthenous, Georgios Karakatsoulis, Eva Minga, Dimitra Chamou, David Allsup, Alejandro Alonso Cabrero, Martin Andres, Darko Antic, Mónica Baile, Panagiotis Baliakas, Sotiria Besikli-Dimou, Dominique Bron, Sofia Chatzileontiadou, Raul Cordoba, Juan Gonzalo Correa, Carolina Cuéllar-GarcíaLorenzo De Paoli, Maria Rosaria De Paolis, Julio Delgado, Maria Dimou, David Donaldson, Mark Catherwood, Michael Doubek, Maria Efstathopoulou, Barbara Eichhorst, Salma Elashwah, Alicia Enrico, Blanca Espinet, Lucia Farina, Angela Ferrari, Myriam Foglietta, Henrik Frederiksen, Moritz Fürstenau, José A. García-Marco, Rocío García-Serra, Rosa Collado, Massimo Gentile, Eva Gimeno, Andreas Glenthøj, Maria Gomes da Silva, Yervand K. Hakobyan, Yair Herishanu, José Ángel Hernández-Rivas, Tobias Herold, Idanna Innocenti, Gilad Itchaki, Ozren Jaksic, Ann Janssens, Оlga B. Kalashnikova, Elżbieta Kalicińska, Arnon P. Kater, Sabina Kersting, Jorge Labrador, Deepesh Lad, Luca Laurenti, Mark David Levin, Enrico Lista, Alberto Lopez-Garcia, Lara Malerba, Roberto Marasca, Monia Marchetti, Juan Marquet, Mattias Mattsson, Francesca R. Mauro, Marta Morawska, Marina Motta, Talha Munir, Roberta Murru, Carsten U. Niemann, Raquel Nunes Rodrigues, Jacopo Olivieri, Lorella Orsucci, Maria Papaioannou, Miguel Arturo Pavlovsky, Inga Piskunova, Viola Maria Popov, Francesca Maria Quaglia, Giulia Quaresmini, Kristian Qvist, Gian Matteo Rigolin, Rosa Ruchlemer, Martin Šimkovič, Martin Špaček, Paolo Sportoletti, Oana Stanca, Tamar Tadmor, Antonella Capasso, Giovanni Del Poeta, Odit Gutwein, Linda Katharina Karlsson, Ivana Milosevic, Fatima Mirás, Gianluigi Reda, Gevorg Saghumyan, Amit Shrestha, Doreen Te Raa, Sanne H. Tonino, Ellen Van Der Spek, Michel van Gelder, Roel van Kampen, Ewa Wasik-Szczepanek, Tomasz Wróbel, Lucrecia Yáñez San Segundo, Mohamed Yassin, Barbara Pocali, Elisabeth Vandenberghe, Sunil Iyengar, Marzia Varettoni, Candida Vitale, Marta Coscia, Alessandro Rambaldi, Emili Montserrat, Antonio Cuneo, Niki Stavroyianni, Livio Trentin, Kostas Stamatopoulos^*, Paolo Ghia^*

^*Corresponding author af dette arbejde

Afdeling for Blodsygdomme

13 Citationer (Scopus)

Abstract

In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p =.0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations.

Originalsprog	Engelsk
Tidsskrift	American Journal of Hematology
Vol/bind	98
Udgave nummer	12
Sider (fra-til)	1856-1868
Antal sider	13
ISSN	0361-8609
DOI	https://doi.org/10.1002/ajh.27093
Status	Udgivet - dec. 2023

Adgang til dokumentet

10.1002/ajh.27093

Andre filer og links

Link to publication in Scopus

Citationsformater

Visentin, A., Chatzikonstantinou, T., Scarfò, L., Kapetanakis, A., Demosthenous, C., Karakatsoulis, G., Minga, E., Chamou, D., Allsup, D., Cabrero, A. A., Andres, M., Antic, D., Baile, M., Baliakas, P., Besikli-Dimou, S., Bron, D., Chatzileontiadou, S., Cordoba, R., Correa, J. G., ... Ghia, P. (2023). The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. American Journal of Hematology, 98(12), 1856-1868. https://doi.org/10.1002/ajh.27093

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. / Visentin, Andrea; Chatzikonstantinou, Thomas; Scarfò, Lydia et al.
I: American Journal of Hematology, Bind 98, Nr. 12, 12.2023, s. 1856-1868.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Visentin, A, Chatzikonstantinou, T, Scarfò, L, Kapetanakis, A, Demosthenous, C, Karakatsoulis, G, Minga, E, Chamou, D, Allsup, D, Cabrero, AA, Andres, M, Antic, D, Baile, M, Baliakas, P, Besikli-Dimou, S, Bron, D, Chatzileontiadou, S, Cordoba, R, Correa, JG, Cuéllar-García, C, De Paoli, L, De Paolis, MR, Delgado, J, Dimou, M, Donaldson, D, Catherwood, M, Doubek, M, Efstathopoulou, M, Eichhorst, B, Elashwah, S, Enrico, A, Espinet, B, Farina, L, Ferrari, A, Foglietta, M, Frederiksen, H, Fürstenau, M, García-Marco, JA, García-Serra, R, Collado, R, Gentile, M, Gimeno, E, Glenthøj, A, da Silva, MG, Hakobyan, YK, Herishanu, Y, Hernández-Rivas, JÁ, Herold, T, Innocenti, I, Itchaki, G, Jaksic, O, Janssens, A, Kalashnikova, ОB, Kalicińska, E, Kater, AP, Kersting, S, Labrador, J, Lad, D, Laurenti, L, Levin, MD, Lista, E, Lopez-Garcia, A, Malerba, L, Marasca, R, Marchetti, M, Marquet, J, Mattsson, M, Mauro, FR, Morawska, M, Motta, M, Munir, T, Murru, R, Niemann, CU, Rodrigues, RN, Olivieri, J, Orsucci, L, Papaioannou, M, Pavlovsky, MA, Piskunova, I, Popov, VM, Quaglia, FM, Quaresmini, G, Qvist, K, Rigolin, GM, Ruchlemer, R, Šimkovič, M, Špaček, M, Sportoletti, P, Stanca, O, Tadmor, T, Capasso, A, Del Poeta, G, Gutwein, O, Karlsson, LK, Milosevic, I, Mirás, F, Reda, G, Saghumyan, G, Shrestha, A, Te Raa, D, Tonino, SH, Van Der Spek, E, van Gelder, M, van Kampen, R, Wasik-Szczepanek, E, Wróbel, T, Segundo, LYS, Yassin, M, Pocali, B, Vandenberghe, E, Iyengar, S, Varettoni, M, Vitale, C, Coscia, M, Rambaldi, A, Montserrat, E, Cuneo, A, Stavroyianni, N, Trentin, L, Stamatopoulos, K & Ghia, P 2023, 'The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL', American Journal of Hematology, bind 98, nr. 12, s. 1856-1868. https://doi.org/10.1002/ajh.27093

@article{d0aed949eeea4e338ffbb5ab1a5e10c8,

title = "The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL",

abstract = "In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p =.0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations.",

author = "Andrea Visentin and Thomas Chatzikonstantinou and Lydia Scarf{\`o} and Anargyros Kapetanakis and Christos Demosthenous and Georgios Karakatsoulis and Eva Minga and Dimitra Chamou and David Allsup and Cabrero, {Alejandro Alonso} and Martin Andres and Darko Antic and M{\'o}nica Baile and Panagiotis Baliakas and Sotiria Besikli-Dimou and Dominique Bron and Sofia Chatzileontiadou and Raul Cordoba and Correa, {Juan Gonzalo} and Carolina Cu{\'e}llar-Garc{\'i}a and {De Paoli}, Lorenzo and {De Paolis}, {Maria Rosaria} and Julio Delgado and Maria Dimou and David Donaldson and Mark Catherwood and Michael Doubek and Maria Efstathopoulou and Barbara Eichhorst and Salma Elashwah and Alicia Enrico and Blanca Espinet and Lucia Farina and Angela Ferrari and Myriam Foglietta and Henrik Frederiksen and Moritz F{\"u}rstenau and Garc{\'i}a-Marco, {Jos{\'e} A.} and Roc{\'i}o Garc{\'i}a-Serra and Rosa Collado and Massimo Gentile and Eva Gimeno and Andreas Glenth{\o}j and {da Silva}, {Maria Gomes} and Hakobyan, {Yervand K.} and Yair Herishanu and Hern{\'a}ndez-Rivas, {Jos{\'e} {\'A}ngel} and Tobias Herold and Idanna Innocenti and Gilad Itchaki and Ozren Jaksic and Ann Janssens and Kalashnikova, {Оlga B.} and El{\.z}bieta Kalici{\'n}ska and Kater, {Arnon P.} and Sabina Kersting and Jorge Labrador and Deepesh Lad and Luca Laurenti and Levin, {Mark David} and Enrico Lista and Alberto Lopez-Garcia and Lara Malerba and Roberto Marasca and Monia Marchetti and Juan Marquet and Mattias Mattsson and Mauro, {Francesca R.} and Marta Morawska and Marina Motta and Talha Munir and Roberta Murru and Niemann, {Carsten U.} and Rodrigues, {Raquel Nunes} and Jacopo Olivieri and Lorella Orsucci and Maria Papaioannou and Pavlovsky, {Miguel Arturo} and Inga Piskunova and Popov, {Viola Maria} and Quaglia, {Francesca Maria} and Giulia Quaresmini and Kristian Qvist and Rigolin, {Gian Matteo} and Rosa Ruchlemer and Martin {\v S}imkovi{\v c} and Martin {\v S}pa{\v c}ek and Paolo Sportoletti and Oana Stanca and Tamar Tadmor and Antonella Capasso and {Del Poeta}, Giovanni and Odit Gutwein and Karlsson, {Linda Katharina} and Ivana Milosevic and Fatima Mir{\'a}s and Gianluigi Reda and Gevorg Saghumyan and Amit Shrestha and {Te Raa}, Doreen and Tonino, {Sanne H.} and {Van Der Spek}, Ellen and {van Gelder}, Michel and {van Kampen}, Roel and Ewa Wasik-Szczepanek and Tomasz Wr{\'o}bel and Segundo, {Lucrecia Y{\'a}{\~n}ez San} and Mohamed Yassin and Barbara Pocali and Elisabeth Vandenberghe and Sunil Iyengar and Marzia Varettoni and Candida Vitale and Marta Coscia and Alessandro Rambaldi and Emili Montserrat and Antonio Cuneo and Niki Stavroyianni and Livio Trentin and Kostas Stamatopoulos and Paolo Ghia",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.",

year = "2023",

month = dec,

doi = "10.1002/ajh.27093",

language = "English",

volume = "98",

pages = "1856--1868",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "12",

}

TY - JOUR

T1 - The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia

T2 - A study by ERIC, the European research initiative on CLL

AU - Visentin, Andrea

AU - Chatzikonstantinou, Thomas

AU - Scarfò, Lydia

AU - Kapetanakis, Anargyros

AU - Demosthenous, Christos

AU - Karakatsoulis, Georgios

AU - Minga, Eva

AU - Chamou, Dimitra

AU - Allsup, David

AU - Cabrero, Alejandro Alonso

AU - Andres, Martin

AU - Antic, Darko

AU - Baile, Mónica

AU - Baliakas, Panagiotis

AU - Besikli-Dimou, Sotiria

AU - Bron, Dominique

AU - Chatzileontiadou, Sofia

AU - Cordoba, Raul

AU - Correa, Juan Gonzalo

AU - Cuéllar-García, Carolina

AU - De Paoli, Lorenzo

AU - De Paolis, Maria Rosaria

AU - Delgado, Julio

AU - Dimou, Maria

AU - Donaldson, David

AU - Catherwood, Mark

AU - Doubek, Michael

AU - Efstathopoulou, Maria

AU - Eichhorst, Barbara

AU - Elashwah, Salma

AU - Enrico, Alicia

AU - Espinet, Blanca

AU - Farina, Lucia

AU - Ferrari, Angela

AU - Foglietta, Myriam

AU - Frederiksen, Henrik

AU - Fürstenau, Moritz

AU - García-Marco, José A.

AU - García-Serra, Rocío

AU - Collado, Rosa

AU - Gentile, Massimo

AU - Gimeno, Eva

AU - Glenthøj, Andreas

AU - da Silva, Maria Gomes

AU - Hakobyan, Yervand K.

AU - Herishanu, Yair

AU - Hernández-Rivas, José Ángel

AU - Herold, Tobias

AU - Innocenti, Idanna

AU - Itchaki, Gilad

AU - Jaksic, Ozren

AU - Janssens, Ann

AU - Kalashnikova, Оlga B.

AU - Kalicińska, Elżbieta

AU - Kater, Arnon P.

AU - Kersting, Sabina

AU - Labrador, Jorge

AU - Lad, Deepesh

AU - Laurenti, Luca

AU - Levin, Mark David

AU - Lista, Enrico

AU - Lopez-Garcia, Alberto

AU - Malerba, Lara

AU - Marasca, Roberto

AU - Marchetti, Monia

AU - Marquet, Juan

AU - Mattsson, Mattias

AU - Mauro, Francesca R.

AU - Morawska, Marta

AU - Motta, Marina

AU - Munir, Talha

AU - Murru, Roberta

AU - Niemann, Carsten U.

AU - Rodrigues, Raquel Nunes

AU - Olivieri, Jacopo

AU - Orsucci, Lorella

AU - Papaioannou, Maria

AU - Pavlovsky, Miguel Arturo

AU - Piskunova, Inga

AU - Popov, Viola Maria

AU - Quaglia, Francesca Maria

AU - Quaresmini, Giulia

AU - Qvist, Kristian

AU - Rigolin, Gian Matteo

AU - Ruchlemer, Rosa

AU - Šimkovič, Martin

AU - Špaček, Martin

AU - Sportoletti, Paolo

AU - Stanca, Oana

AU - Tadmor, Tamar

AU - Capasso, Antonella

AU - Del Poeta, Giovanni

AU - Gutwein, Odit

AU - Karlsson, Linda Katharina

AU - Milosevic, Ivana

AU - Mirás, Fatima

AU - Reda, Gianluigi

AU - Saghumyan, Gevorg

AU - Shrestha, Amit

AU - Te Raa, Doreen

AU - Tonino, Sanne H.

AU - Van Der Spek, Ellen

AU - van Gelder, Michel

AU - van Kampen, Roel

AU - Wasik-Szczepanek, Ewa

AU - Wróbel, Tomasz

AU - Segundo, Lucrecia Yáñez San

AU - Yassin, Mohamed

AU - Pocali, Barbara

AU - Vandenberghe, Elisabeth

AU - Iyengar, Sunil

AU - Varettoni, Marzia

AU - Vitale, Candida

AU - Coscia, Marta

AU - Rambaldi, Alessandro

AU - Montserrat, Emili

AU - Cuneo, Antonio

AU - Stavroyianni, Niki

AU - Trentin, Livio

AU - Stamatopoulos, Kostas

AU - Ghia, Paolo

PY - 2023/12

Y1 - 2023/12

N2 - In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p =.0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations.

AB - In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p =.0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations.

UR - http://www.scopus.com/inward/record.url?scp=85172666179&partnerID=8YFLogxK

U2 - 10.1002/ajh.27093

DO - 10.1002/ajh.27093

M3 - Journal article

C2 - 37772428

AN - SCOPUS:85172666179

SN - 0361-8609

VL - 98

SP - 1856

EP - 1868

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 12

ER -

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater